

Jeffrey D Lifson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6938211/publications.pdf>

Version: 2024-02-01

72
papers

9,524
citations

76326

40
h-index

82547

72
g-index

78
all docs

78
docs citations

78
times ranked

8161
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. <i>Science Translational Medicine</i> , 2022, 14, eabl3836.	12.4	50
2	Myeloid cell tropism enables MHC-E-restricted CD8 ⁺ T cell priming and vaccine efficacy by the RhCMV/SIV vaccine. <i>Science Immunology</i> , 2022, 7, .	11.9	16
3	Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 657424.	4.8	2
4	Cytomegaloviral determinants of CD8 ⁺ T cell programming and RhCMV/SIV vaccine efficacy. <i>Science Immunology</i> , 2021, 6, .	11.9	34
5	Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy. <i>Science</i> , 2021, 372, .	12.6	32
6	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure. <i>Journal of Virology</i> , 2021, 95, .	3.4	21
7	Recombinant Herpesvirus Vectors: Durable Immune Responses and Durable Protection against Simian Immunodeficiency Virus SIVmac239 Acquisition. <i>Journal of Virology</i> , 2021, 95, e0033021.	3.4	2
8	Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy. <i>PLoS Pathogens</i> , 2021, 17, e1009278.	4.7	18
9	Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	1
10	Genetically barcoded SIV reveals the emergence of escape mutations in multiple viral lineages during immune escape. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 494-502.	7.1	9
11	Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV. <i>Frontiers in Immunology</i> , 2020, 11, 449.	4.8	29
12	Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques. <i>PLoS ONE</i> , 2020, 15, e0228163.	2.5	4
13	Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 225-237.	4.1	5
14	A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	80
15	AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	35
16	Evaluation of an antibody to $\text{CD4}^{\text{v}} \text{CD7}$ in the control of SIVmac239- <i>nef-stop</i> infection. <i>Science</i> , 2019, 365, 1025-1029.	12.6	29
17	Blocking $\text{CD4}^{\text{v}} \text{CD7}$ integrin binding to SIV does not improve virologic control. <i>Science</i> , 2019, 365, 1033-1036.	12.6	31
18	Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies. <i>Molecular Therapy</i> , 2019, 27, 650-660.	8.2	42

#	ARTICLE	IF	CITATIONS
19	Defining early SIV replication and dissemination dynamics following vaginal transmission. <i>Science Advances</i> , 2019, 5, eaav7116.	10.3	30
20	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10504-10509.	7.1	14
21	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , 2019, 15, e1007632.	4.7	20
22	<i>In Vivo</i> Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses. <i>Journal of Virology</i> , 2019, 94, .	3.4	24
23	Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions. <i>Journal of Virology</i> , 2018, 92, .	3.4	8
24	Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. <i>PLoS Pathogens</i> , 2018, 14, e1007395.	4.7	37
25	Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. <i>Nature Medicine</i> , 2018, 24, 1430-1440.	30.7	98
26	Control of Heterologous Simian Immunodeficiency Virus SIV _{smE660} Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	39
27	Early antibody therapy can induce long-lasting immunity to SHIV. <i>Nature</i> , 2017, 543, 559-563.	27.8	244
28	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	45
29	A single gp120 residue can affect HIV-1 tropism in macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006572.	4.7	28
30	Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy. <i>PLoS Pathogens</i> , 2017, 13, e1006359.	4.7	77
31	Impact of early cART in the gut during acute HIV infection. <i>JCI Insight</i> , 2016, 1, .	5.0	56
32	Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys. <i>Cell</i> , 2016, 165, 656-667.	28.9	144
33	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. <i>Nature</i> , 2016, 533, 105-109.	27.8	281
34	Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. <i>Science</i> , 2016, 353, 1045-1049.	12.6	129
35	Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection. <i>Journal of Virology</i> , 2016, 90, 8435-8453.	3.4	19
36	Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 546-554.	3.8	40

#	ARTICLE	IF	CITATIONS
37	Envelope residue 375 substitutions in simian human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	7.1	170
38	Defining HIV and SIV Reservoirs in Lymphoid Tissues. <i>Pathogens and Immunity</i> , 2016, 1, 68.	3.1	212
39	Generation and characterization of a SIVmac239 clone corrected at four suboptimal nucleotides. <i>Retrovirology</i> , 2015, 12, 49.	2.0	6
40	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. <i>Science Translational Medicine</i> , 2015, 7, 319ra206.	12.4	390
41	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. <i>Nature</i> , 2015, 519, 87-91.	27.8	265
42	B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. <i>Nature Medicine</i> , 2015, 21, 132-139.	30.7	439
43	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	12.6	303
44	AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. <i>PLoS Pathogens</i> , 2015, 11, e1005090.	4.7	77
45	Tracking the Luminal Exposure and Lymphatic Drainage Pathways of Intravaginal and Intrarectal Inocula Used in Nonhuman Primate Models of HIV Transmission. <i>PLoS ONE</i> , 2014, 9, e92830.	2.5	50
46	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. <i>Journal of Immunology</i> , 2014, 193, 6172-6183.	0.8	34
47	Molecularly Tagged Simian Immunodeficiency Virus SIVmac239 Synthetic Swarm for Tracking Independent Infection Events. <i>Journal of Virology</i> , 2014, 88, 8077-8090.	3.4	46
48	Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. <i>Nature</i> , 2014, 511, 601-605.	27.8	422
49	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. <i>Cell Host and Microbe</i> , 2014, 16, 412-418.	11.0	47
50	HIV-1 induced AIDS in monkeys. <i>Science</i> , 2014, 344, 1401-1405.	12.6	76
51	The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial. <i>PLoS ONE</i> , 2014, 9, e116306.	2.5	56
52	Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. <i>Nature</i> , 2013, 503, 277-280.	27.8	424
53	Immune clearance of highly pathogenic SIV infection. <i>Nature</i> , 2013, 502, 100-104.	27.8	548
54	Cytomegalovirus Vectors Violate CD8 T Cell Epitope Recognition Paradigms. <i>Science</i> , 2013, 340, 1237874.	12.6	397

#	ARTICLE	IF	CITATIONS
55	Reduced Inflammation and Lymphoid Tissue Immunopathology in Rhesus Macaques Receiving Anti-Tumor Necrosis Factor Treatment During Primary Simian Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2013, 207, 880-892.	4.0	54
56	The Frequency of CD4 ⁺ high Memory CD4 ⁺ T Cells Correlates With Susceptibility to Rectal Simian Immunodeficiency Virus Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 325-331.	2.1	60
57	Comparative Characterization of Transfection- and Infection-Derived Simian Immunodeficiency Virus Challenge Stocks for <i>In Vivo</i> Nonhuman Primate Studies. <i>Journal of Virology</i> , 2013, 87, 4584-4595.	3.4	71
58	Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIV _{mac251} at Challenge Exposure. <i>Journal of Virology</i> , 2013, 87, 3538-3548.	3.4	52
59	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV _{mac251} Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. <i>Journal of Virology</i> , 2013, 87, 1708-1719.	3.4	130
60	DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2975-2980.	7.1	71
61	ADCC Develops Over Time during Persistent Infection with Live-Attenuated SIV and Is Associated with Complete Protection against SIV _{mac251} Challenge. <i>PLoS Pathogens</i> , 2012, 8, e1002890.	4.7	156
62	Restricted Replication of Xenotropic Murine Leukemia Virus-Related Virus in Pigtailed Macaques. <i>Journal of Virology</i> , 2012, 86, 3152-3166.	3.4	16
63	New Paradigms for HIV/AIDS Vaccine Development. <i>Annual Review of Medicine</i> , 2012, 63, 95-111.	12.2	139
64	Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. <i>Nature</i> , 2011, 473, 523-527.	27.8	902
65	A macaque model of HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4425-4429.	7.1	150
66	Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy. <i>Journal of Virology</i> , 2009, 83, 1501-1510.	3.4	14
67	Glycerol monolaurate prevents mucosal SIV transmission. <i>Nature</i> , 2009, 458, 1034-1038.	27.8	563
68	Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. <i>Nature Medicine</i> , 2009, 15, 293-299.	30.7	621
69	Longitudinal <i>In Vivo</i> Positron Emission Tomography Imaging of Infected and Activated Brain Macrophages in a Macaque Model of Human Immunodeficiency Virus Encephalitis Correlates with Central and Peripheral Markers of Encephalitis and Areas of Synaptic Degeneration. <i>American Journal of Pathology</i> , 2008, 172, 1603-1616.	3.8	44
70	Gag-Specific CD8 ⁺ T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression. <i>Journal of Immunology</i> , 2007, 178, 2746-2754.	0.8	247
71	Generation of Simian-Tropic HIV-1 by Restriction Factor Evasion. <i>Science</i> , 2006, 314, 95-95.	12.6	140
72	Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. <i>Journal of Medical Primatology</i> , 2005, 34, 303-312.	0.6	311